Inhibikase Therapeutics Q3 2026 earnings
Net loss widened to $20.5 million despite a $50 million equity raise, driven by increased R&D spending for the Phase 3 IMPROVE-PAH study.
Headline numbers
not stated in the 8-K
Revenue breakdown
not stated in the 8-K
Margins and costs
- Gross margin not stated in the 8-K
- Operating expenses $22.2 million (+96% YoY)
- One-offs in the quarter Change in fair value contingent consideration: $0 (vs $0.5m prior); Non-cash write-off of in-process R&D: $7.4 million (nine months)
- Effective tax rate not stated in the 8-K
- Non-GAAP bridge Stock-based compensation and non-cash accretion on marketable securities are added back to GAAP net loss.
KPIs
| Metric | Actual | Prior quarter | Prior year | Change |
|---|---|---|---|---|
| Cash, cash equivalents and marketable securities | $193.3 million | $159.0 million | $178.8 million | +21% |
| Shares outstanding | 140.3 million | 132.0 million | 90.0 million | +6% |
| Clinical sites activated | 79 | 43 | 0 | +84% |
| Country regulatory approvals | 28 | 26 | 0 | +8% |
Guidance
not stated in the 8-K
What drove it
- Revenue story No revenue reported; company is clinical-stage.
- EPS story Net loss per share increased due to higher operating expenses and a larger share count.
- One-off check Non-cash write-off of in-process R&D of $7.4 million (nine months) and stock-based compensation of $1.8 million (nine months) associated with the CorHepta acquisition.
The good
- Cash position increased to $193.3 million following $50 million equity raise in July.
- Clinical development advanced with 79 sites activated and 28 country regulatory approvals.
The bad
- Net loss widened to $20.5 million from $11.9 million in the prior year.
- R&D expenses increased to $15.0 million from $7.6 million in the prior year.
The ugly
- none
Open questions
- The release does not quantify the remaining cash runway or the specific date of the topline data readout for Part B of the Phase 3 study.
- The release does not disclose the specific timing or results of the interim safety readout mentioned in the forward-looking statements.
Full release
Inhibikase Therapeutics (IKT) earnings release, November 10, 2026
Inhibikase Therapeutics Announces Third Quarter 2026
Financial Results and Highlights Recent Activity
WILMINGTON, Del., November 10, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or
“Company”), a clinical-stage pharmaceutical company developing
IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended September 30, 2026, and highlighted recent developments.
“During our third quarter and in recent weeks we continued to advance our Phase 3
IMPROVE-PAH study, for which we have obtained 28 country regulatory approvals in the U.S. and E.U., with 79 clinical sites activated across a range of countries,” said
Mark Iwicki, Chief Executive Officer of Inhibikase. “We continue to expand our clinical footprint and look forward to additional country and site activations over the coming months. Supported by the $50 million proceeds from the sale of shares to RA Capital in July, Inhibikase is well-positioned to advance
IKT-001 toward its potential as the first once-daily oral anti-proliferative offering significant potential benefits to the PAH patient population.”
Recent Developments¹
Nonclinical and Development Update
Over the last few months and extending into 2027, the Company has enhanced its focus on additional nonclinical activities that have the potential to broaden the scientific rationale for
IKT-001 across the following themes:
Investor Conferences
Inhibikase is participating in the following upcoming investor conferences:
Jefferies Global Healthcare Conference
November 16–19, 2026
London, United Kingdom
Format:
Fireside Chat with Mark Iwicki of Inhibikase and Dennis Ding, Jefferies Research
Date: Monday, November 16
Webcast: Click here
9th
Annual Evercore Healthcare Conference
November 30–December 2, 2026
Coral Gables, Florida
Mr. Iwicki will participate in one-on-one investor meetings on Tuesday, December 1. Investors interested in scheduling a meeting should contact their Evercore representative.²
Financial Results
Cash Position:
As of September 30, 2026, cash, cash equivalents and marketable securities were $193.3 million. In July 2026, the Company announced that it had sold 25,000,000 shares of the Company’s common stock to RA Capital Management through its ATM facility for gross proceeds of $50 million. The Company expects that the additional capital raised through this financing, together with existing cash reserves, will support operations through topline data readout in Part B of the ongoing global Phase 3
IMPROVE-PAH clinical study, assuming the full and timely exercise of the outstanding Series A and B Warrants.
As of September 30, 2026, there were 140.3 million shares of common stock and 60.6 million pre-funded warrants outstanding.
Net Loss:
Net loss for the quarter ended September 30, 2026, was
$20.5 million, or $0.10 per share, compared to a net loss of $11.9 million, or $0.13 per share in the quarter ended September 30, 2025. Net loss for the nine months ended September 30, 2026, was $56.4 million, or $0.31 per share, compared to a net loss of $35.5 million, or $0.40 per share, for the nine months ended September 30, 2025.
R&D Expenses:
Research and development expenses were $15.0 million for the quarter ended September 30, 2026, compared to $7.6 million for the quarter ended September 30, 2025. Research and development expenses were $39.2 million for the nine months ended September 30, 2026, compared to $23.4 million for the nine months ended September 30, 2025, which included a non-cash write-off of in-process research and development of $7.4 million and $1.8 million of stock-based compensation expense, both associated with the Company’s acquisition of CorHepta in February 2025.
SG&A Expenses:
Selling, general and administrative expenses for the quarter ended September 30, 2026 were $7.2 million, compared to
$5.6 million for the quarter ended September 30, 2025. Selling, general and administrative expenses for the nine months ended September 30, 2026 were $22.3 million, compared to $16.8 million for the nine months ended
September 30, 2025, which included $1.0 million of severance expenses for former senior executives of the Company.
About Inhibikase
(www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (“PAH”), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as
“c-Kit,” has been implicated. Our lead product candidate is
IKT-001, a prodrug of imatinib mesylate (“imatinib”), for PAH which is an orphan indication. Imatinib was first approved in the United States in 2001 for various cancers and blood disorders and, following more than 20 years of clinical use, has a well-characterized safety profile with the first reported use of imatinib in PAH occurring in 2005. PAH is a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance that affects approximately 50,000 Americans. Our single pivotal Phase 3 clinical study in PAH in approximately 180 sites around the world, named
IMPROVE-PAH
(
I
KT-001 for
M easuring
P ulmonary Vascular
R esistance and
O utcome
V ariables in a Phase 3
E valuation of
PAH), is actively enrolling patients.³
Social Media Disclaimer
Investors and others should note that the Company announces material financial information to investors using its investor relations website, press releases,... (truncated)also use LinkedIn as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under
Regulation FD.
Financial statements
Income Statement
Three Months Ended September 30, — (Unaudited)
| Three Months Ended September 30, – 2026 | Three Months Ended September 30, – 2025 | Nine Months Ended September 30, – 2026 | Nine Months Ended September 30, – 2025 | |
|---|---|---|---|---|
| Costs and expenses: | ||||
| Research and development | 14,999,866 | 7,649,697 | 39,232,480 | 23,434,243 |
| Selling, general and administrative | 7,229,191 | 5,611,503 | 22,262,845 | 16,780,525 |
| Change in fair value contingent consideration | -492,827 | -373,354 | -2,016,111 | |
| Total costs and expenses | 22,229,057 | 12,768,373 | 61,121,971 | 38,198,657 |
| Loss from operations | -22,229,057 | -12,768,373 | -61,121,971 | -38,198,657 |
| Other income | 1,761,723 | 838,093 | 4,682,566 | 2,674,119 |
| Net loss | -20,467,334 | -11,930,280 | -56,439,405 | -35,524,538 |
| Other comprehensive loss | ||||
| Unrealized (loss) gain on marketable securities | -36,607 | -1,245 | -131,163 | 33,059 |
| Comprehensive loss | -20,503,941 | -11,931,525 | -56,570,568 | -35,491,479 |
| Net loss per share – basic and diluted | -0.1 | -0.13 | -0.31 | -0.4 |
| Weighted-average number of shares – basic and diluted | 196,938,811 | 90,050,973 | 181,362,655 | 89,867,805 |
Balance Sheet
September 30, 2026 — (Unaudited)
| September 30, 2026 – (Unaudited) | December 31, 2025 – (Note 1) | |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | 51,701,197 | 139,220,208 |
| Marketable securities | 141,619,768 | 39,543,820 |
| Prepaid research and development | 3,998,159 | 1,001,993 |
| Prepaid expenses and other current assets | 1,412,941 | 343,374 |
| Total current assets | 198,732,065 | 180,109,395 |
| Prepaid research and development, noncurrent | 2,780,307 | 1,000,000 |
| Other assets | 239,577 | 95,121 |
| Total assets | 201,751,949 | 181,204,516 |
| Current liabilities: | ||
| Accounts payable | 947,993 | 1,158,054 |
| Accrued expenses and other current liabilities (see Note 6) | 12,008,758 | 4,081,282 |
| Contingent consideration liability | 3,061,501 | |
| Total current liabilities | 12,956,751 | 8,300,837 |
| Total liabilities | 12,956,751 | 8,300,837 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 500,000,000 shares authorized at September 30, 2026 and December 31, 2025; 140,269,633 and 131,691,237 shares issued and outstanding (including 0 and 4,149,252 contingently issuable shares - see Note 9) at September 30, 2026 and December 31, 2025, respectively | 140,270 | 131,691 |
| Additional paid-in capital | 387,883,494 | 315,429,986 |
| Accumulated other comprehensive (loss) income | -109,361 | 21,802 |
| Accumulated deficit | -199,119,205 | -142,679,800 |
| Total stockholders’ equity | 188,795,198 | 172,903,679 |
| Total liabilities and stockholders’ equity | 201,751,949 | 181,204,516 |
Cash Flow
Nine months ended September 30, — (Unaudited)
| Nine months ended September 30, – 2026 | Nine months ended September 30, – 2025 | |
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | -56,439,405 | -35,524,538 |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 60,499 | |
| Stock-based compensation expense | 16,433,584 | 10,776,144 |
| Write-off of in-process research and development | 7,357,294 | |
| Change in fair value contingent consideration | -373,354 | -2,016,111 |
| Non-cash accretion on marketable securities | -3,203,308 | -570,503 |
| Changes in operating assets and liabilities: | ||
| Operating lease right-of-use assets | 101,437 | |
| Prepaid expenses and other current assets | -1,069,567 | 257,321 |
| Current and non-current prepaid research and development | -4,776,473 | -1,129,258 |
| Other assets | -144,456 | -57,913 |
| Accounts payable | -210,061 | -390,699 |
| Operating lease liabilities | -110,517 | |
| Accrued expenses and other current liabilities | 7,927,476 | 976,353 |
| Net cash used in operating activities | -41,855,564 | -20,270,491 |
| Cash flows from investing activities | ||
| Purchases of equipment and improvements | -13,399 | |
| Purchases of investments - marketable securities | -221,303,803 | -38,996,000 |
| Maturities of investments - marketable securities | 122,300,000 | 41,600,000 |
| Acquired in-process research and development | -438,624 | |
| Net cash provided by (used in) investing activities | -99,003,803 | 2,151,977 |
| Cash flows from financing activities | ||
| Deferred offering costs | -385,062 | |
| Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs of $1.3 million | 52,011,159 | 150 |
| Proceeds from the exercise of Series A-1 warrants | 1,000,100 | |
| Exchange of common stock for pre-funded warrants | -18,030 | |
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking terminology such as “believes,” “expects,” “may,”
“will,” “should,” “anticipates,” “plans,” or similar expressions or the negative of these terms and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the potential of
IKT-001, including its potential to become a once-daily oral anti-proliferative treatment for PAH and its potential benefits to patients with PAH, the advancement of the Company’s global pivotal Phase 3 clinical study of
IKT-001 in PAH, including the timing, design, conduct and anticipated interim safety readout of the
IMPROVE-PAH study and related regulatory submissions, the
Company’s ability to obtain additional regulatory approvals for the
IMPROVE-PAH study, including any approvals needed to evaluate combination therapy in Part B, the Company’s beliefs regarding the potential advantages of the Phase 3 clinical study of
IKT-001, the Company’s nonclinical studies of
IKT-001 in combination with sotatercept and its potential use in Group 2 and Group 3 pulmonary hypertension, including the expected timing and results of those studies and potential therapeutic benefits, the potential benefits of Orphan Drug Designation, the Company’s expectations regarding its cash runway and ability to fund operations through the topline data readout from Part B of
IMPROVE-PAH, expectations regarding the exercise of the outstanding Series A and B Warrants, or future events or conditions. These forward-looking statements are based on Inhibikase’s current expectations and assumptions. Such statements are subject to certain risks and uncertainties, which could cause Inhibikase’s actual results to differ materially from those anticipated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include our ability to execute a Phase 3 study to evaluate
IKT-001 as a treatment for PAH, as well as such other factors that are included in our periodic reports on Form
10-K and Form
10-Q that we file with the U.S. Securities and Exchange Commission. Any forward-looking statement in this release speaks only as of the date of this release. Inhibikase undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws.
Contacts:
Investor Relations:
Michael Moyer
LifeSci Advisors mmoyer@lifesciadvisors.com
___tables to follow__⁴
Inhibikase Therapeutics, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)⁵
Inhibikase Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(Unaudited)
Inhibikase Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)